Paradigm Capital Management Inc. NY Makes New Investment in Natera, Inc. $NTRA

Paradigm Capital Management Inc. NY acquired a new stake in Natera, Inc. (NASDAQ:NTRA) in the second quarter, HoldingsChannel reports. The institutional investor acquired 90,400 shares of the medical research company’s stock, valued at approximately $24,539,000. Natera makes up about 0.7% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 29th largest position.

Other large investors also recently modified their holdings of the company. Horizon Investments LLC increased its position in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares during the last quarter. First Horizon Corp grew its stake in Natera by 5.5% during the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after purchasing an additional 51 shares in the last quarter. Siemens Fonds Invest GmbH grew its stake in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after purchasing an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH grew its stake in Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 62 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Barclays reaffirmed an “overweight” rating and issued a $340.00 target price on shares of Natera in a research report on Friday, August 7th. The Goldman Sachs Group started coverage on shares of Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price target for the company. Sanford C. Bernstein began coverage on shares of Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target for the company. Wells Fargo & Company upped their price target on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Natera from $315.00 to $360.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $319.38.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares of the company’s stock, valued at $34,264,866.02. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 177,955 shares of company stock valued at $40,704,193 over the last three months. 5.05% of the stock is currently owned by company insiders.

Natera Stock Down 1.3%

NASDAQ:NTRA opened at $327.72 on Tuesday. The business’s 50 day moving average is $276.45 and its two-hundred day moving average is $230.09. Natera, Inc. has a 52 week low of $157.43 and a 52 week high of $333.56. The company has a market cap of $47.24 billion, a PE ratio of -240.97 and a beta of 1.51.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business’s revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.74) EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.